Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study
Biran, N., Ip, A., Ahn, J., Go, R. C., Wang, S., Mathura, S., Sinclaire, B. A., Bednarz, U., Marafelias, M., Hansen, E., Siegel, D. S., Goy, A. H., Pecora, A. L., Sawczuk, I. S., Koniaris, L. S., Simwenyi, M., Varga, D. W., Tank, L. K., Stein, A. A., … Goldberg, S. L. (2020). Tocilizumab among patients with COVID-19 in the intensive care unit: A multicentre observational study. The Lancet Rheumatology, 0(0). https://doi.org/10.1016/S2665-9913(20)30277-0
0
0
Tags
SARS-CoV-2 (COVID-19)
Biomedical Sciences
Related
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial
Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis
Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study
Effect of pre-exposure use of hydroxychloroquine on COVID-19 mortality: a population-based cohort study in patients with rheumatoid arthritis or systemic lupus erythematosus using the OpenSAFELY platform
Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial